Activity-independent targeting of mTOR to lysosomes in primary osteoclasts

Andrew Wang1, Luciene R Carraro-Lacroix1, Celeste Owen2

  • 1Faculty of Dentistry, University of Toronto, Toronto, ON, Canada.

Scientific Reports
|June 9, 2017
PubMed

Insights

Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) targets lysosomes independently of its activity. This challenges the idea that mTORC1 universally disassociates from lysosomes during starvation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Mammalian target of rapamycin (mTOR) complex 1 (mTORC1) is a key regulator of cell growth, proliferation, and autophagy.
  • mTORC1 activity is linked to lysosomal acidification mediated by vacuolar H+-ATPases (V-ATPases), but the precise role of V-ATPases in mTORC1 signaling remains unclear.
  • mTORC1 is typically found on lysosomes and is thought to disassociate during amino acid starvation.

Purpose of the Study:

  • To investigate the role of V-ATPases in regulating mTORC1 localization and activity.
  • To determine if mTORC1 disassociation from lysosomes during starvation is a universal mechanism.

Main Methods:

  • Utilized primary osteoclasts from mice with a V-ATPase a3 subunit mutation (R740S) leading to impaired lysosomal acidification.
  • Employed confocal microscopy, cell fractionation, and lysosome purification to analyze mTOR localization and activity.
  • Assessed mTOR/lysosome co-localization and lysosomal positioning.

Main Results:

  • In osteoclasts with defective V-ATPases, mTOR remained localized on the lysosomal surface even when mTOR activity was inhibited.
  • Demonstrated that mTOR targeting to lysosomes in osteoclasts is independent of mTOR kinase activity.
  • Found that mTORC1 does not universally disassociate from lysosomes during starvation in these cells.

Conclusions:

  • Lysosomal V-ATPases do not appear to regulate mTORC1 targeting to the lysosome in osteoclasts.
  • mTORC1 localization to lysosomes in osteoclasts is an activity-independent process.
  • The disassociation of mTORC1 from lysosomes during starvation is not a universal phenomenon.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K